Liaw Patricia C Y, Esmon Charles T, Kahnamoui Kamyar, Schmidt Shelley, Kahnamoui Sarah, Ferrell Gary, Beaudin Suzanne, Julian Jim A, Weitz Jeffrey I, Crowther Mark, Loeb Mark, Cook Deborah
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Blood. 2004 Dec 15;104(13):3958-64. doi: 10.1182/blood-2004-03-1203. Epub 2004 Aug 19.
Activated protein C (APC) supplementation significantly reduces mortality in patients with severe sepsis, presumably by down-regulating coagulation, inflammation, and apoptosis. In vivo, endogenous APC is generated from protein C (PC) "on demand" in response to elevated thrombin levels. Thrombomodulin and endothelial cell protein C receptor are endothelial receptors required to generate APC endogenously. Since these receptors may be down-regulated in sepsis, we measured plasma markers of APC generation in 32 patients with severe sepsis to determine whether APC generation is impaired and whether markers of APC generation correlate with 28-day mortality. Relative to normals, all patients had elevated F1 + 2 and thrombin-antithrombin complex (TAT) levels (markers of thrombin generation and inhibition, respectively), and 28 of 32 patients had reduced PC levels. In 20 patients, APC levels paralleled elevated F1 + 2 levels, whereas 12 patients had low APC levels despite elevated F1 + 2 levels, suggesting that APC generation is impaired in the latter. No significant differences exist between survivors and nonsurvivors with respect to baseline PC levels, F1 + 2 levels, and APACHE II (acute physiology and chronic health evaluation) scores. Baseline APC levels were higher in survivors (P = .024), and baseline F1 + 2/APC ratios were lower in survivors (P = .047). Larger studies are warranted to establish whether APC generation profiles aid in managing sepsis.
补充活化蛋白C(APC)可显著降低严重脓毒症患者的死亡率,这可能是通过下调凝血、炎症和细胞凋亡实现的。在体内,内源性APC是在凝血酶水平升高时,由蛋白C(PC)“按需”生成的。血栓调节蛋白和内皮细胞蛋白C受体是内源性生成APC所需的内皮受体。由于这些受体在脓毒症中可能下调,我们检测了32例严重脓毒症患者的APC生成血浆标志物,以确定APC生成是否受损,以及APC生成标志物是否与28天死亡率相关。相对于正常人,所有患者的F1 + 2和凝血酶 - 抗凝血酶复合物(TAT)水平均升高(分别为凝血酶生成和抑制的标志物),32例患者中有28例PC水平降低。在20例患者中,APC水平与升高的F1 + 2水平平行,而12例患者尽管F1 + 2水平升高,但APC水平较低,这表明后者的APC生成受损。幸存者和非幸存者在基线PC水平、F1 + 2水平和急性生理与慢性健康评估(APACHE II)评分方面无显著差异。幸存者的基线APC水平较高(P = .024),幸存者的基线F1 + 2/APC比值较低(P = .047)。需要进行更大规模的研究来确定APC生成谱是否有助于脓毒症的管理。